Stock Analysis on Net
Stock Analysis on Net

GlaxoSmithKline PLC (NYSE:GSK)

This company has been moved to the archive! The financial data has not been updated since February 27, 2015.

Common-Size Income Statement

GlaxoSmithKline PLC, common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Turnover 100.00 100.00 100.00 100.00 100.00
Cost of sales -31.83 -32.39 -29.87 -26.77 -26.74
Gross profit 68.17% 67.61% 70.13% 73.23% 73.26%
Selling, general and administration -35.84 -31.99 -33.06 -32.23 -45.97
Research and development -15.00 -14.80 -15.01 -14.64 -15.70
Royalty income 1.35 1.46 1.16 1.13 1.04
Impairment of equity investments -0.11 -0.26 -0.10 -0.28 -0.23
Disposal of equity investments 0.67 0.14 0.07 0.04 0.06
Disposal of businesses and assets 1.06 5.33 2.50 1.18 0.80
Gain on settlement of pre-existing collaborations on acquisition of HGS 0.00 0.00 0.88 0.00 0.00
Gain on acquisition of the Shionogi-ViiV Healthcare joint venture 0.00 0.00 1.32 0.00 0.00
Fair value remeasurements on contingent consideration recognised in business combinations -3.35 -0.95 -0.05 0.00 0.00
Fair value adjustments on derivative financial instruments -1.36 0.05 0.01 0.04 -0.02
Other income (expense) 0.04 -0.07 0.11 0.05 0.08
Other operating income -3.04% 4.24% 4.75% 1.02% 0.69%
Operating profit 15.64% 26.52% 27.97% 28.51% 13.32%
Interest income 0.29 0.22 0.28 0.31 0.36
Realised gains on liquid investments 0.00 0.00 0.02 0.02 0.00
Fair value adjustments on derivatives at fair value through profit or loss 0.01 0.01 0.01 0.00 0.05
Finance income 0.30% 0.23% 0.30% 0.33% 0.41%
Interest expense -2.99 -2.74 -2.82 -2.72 -2.70
Fair value hedges 0.02 0.00 0.00 0.00 0.00
Fair value movements on other derivatives at fair value through profit or loss -0.07 -0.01 -0.05 -0.05 -0.06
Reclassification of cash flow hedge from other comprehensive income 0.00 0.00 0.00 0.00 -0.01
Unwinding of discounts on provisions -0.07 -0.05 -0.06 -0.04 -0.06
Movements on amounts owed to non-controlling interests 0.00 -0.01 -0.04 -0.03 0.00
Other finance expense -0.06 -0.08 -0.09 -0.07 -0.09
Finance costs -3.16% -2.89% -3.06% -2.92% -2.93%
Profit on disposal of interest in associates 0.00 1.06 0.00 2.14 0.03
Share of after tax profits of associates and joint ventures 0.13 0.16 0.11 0.05 0.29
Profit before taxation 12.90% 25.08% 25.32% 28.11% 11.12%
Taxation -0.60 -3.84 -7.37 -8.18 -4.59
Profit after taxation for the year 12.31% 21.23% 17.95% 19.93% 6.53%
Profit attributable to non-controlling interests -0.33 -0.72 -0.68 -0.72 -0.77
Profit attributable to shareholders 11.98% 20.51% 17.27% 19.21% 5.76%

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Income statement item Description The company
Operating profit The net result for the period of deducting operating expenses from operating revenues. GlaxoSmithKline PLC operating profit as a percentage of turnover decreased from 2012 to 2013 and from 2013 to 2014.
Profit before taxation Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. GlaxoSmithKline PLC profit before taxation as a percentage of turnover decreased from 2012 to 2013 and from 2013 to 2014.
Profit attributable to shareholders The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. GlaxoSmithKline PLC profit attributable to shareholders as a percentage of turnover increased from 2012 to 2013 but then decreased significantly from 2013 to 2014.